The Biospecimen Core (Core A) provides part of the infrastructure support for Projects 1-3. This Core will provide a well-organized and standardized system of specimen collection, storage, distribution and related clinical/research information dissemination that is based on over two decades of experience. There will be consistency and quality assurance in the pathological analysis of tissue specimens. The Biospecimen Core is also involved in the maintenance of a large series of prostate cancer xenograft lines developed by Core investigators. These xenografts are used for a number of studies by the POI investigators and each study is overseen by Core personnel. Overall, the operations of this Core group into 5 components: 1. Specimen acquisition, processing, quality control, storage and accessioning into databases; 2. A development program to continually improve the quality and efficiency with which we obtain tissue samples and derivative products; 3. A prostate cancer xenograft maintenance, development and study program. 4. Laboratory services, including interpretation of tissues and tissue localization studies by a urologic pathologist, immunohistochemistry (IHC), quantitative RT-PCR, and immunoassays, i.e. PSA, and tissue culture. The Core will also perform pre-clinical studies using our xenograft resources;and 5. An administrative program to obtain samples from minority patients, prioritize the distribution of specimens, conduct a quality control program, and to ensure patient confidentiality and compliance with IRB requirements. Furthermore, the Core provides biostatistical support to all of the project investigators. The performance of each of the research projects detailed in this program project mandates that investigators have ready access to well documented clinical specimens and relevant biological models. The investigators directing the Biospecimen Core also make it a policy to provide excess prostate cancer specimen resources to non-PPG investigators on a world-wide basis. Overall, the Biospecimen Core is a critical component of this P01 program project.

Public Health Relevance

The Biospecimen Core is not hypothesis driven yet it is an essential component of this POI that enables the investigative teams to conduct hypothesis driven projects. Without adequate specimens and tumor models, both in quantity and quality, the science conducted by these investigators can not be robust. This Core assures that they are and futhermore provides outstanding statistical support for analyses of data.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA085859-10
Application #
8518251
Study Section
Special Emphasis Panel (ZCA1-RPRB-O)
Project Start
Project End
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
10
Fiscal Year
2013
Total Cost
$502,829
Indirect Cost
$116,305
Name
University of Washington
Department
Type
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Montgomery, Bruce; Tretiakova, Maria S; Joshua, Anthony M et al. (2017) Neoadjuvant Enzalutamide Prior to Prostatectomy. Clin Cancer Res 23:2169-2176
Martin, P L; Yin, J-J; Seng, V et al. (2017) Androgen deprivation leads to increased carbohydrate metabolism and hexokinase 2-mediated survival in Pten/Tp53-deficient prostate cancer. Oncogene 36:525-533
Suominen, Mari I; Fagerlund, Katja M; Rissanen, Jukka P et al. (2017) Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models. Clin Cancer Res 23:4335-4346
Don-Doncow, Nicholas; Marginean, Felicia; Coleman, Ilsa et al. (2017) Expression of STAT3 in Prostate Cancer Metastases. Eur Urol 71:313-316
Wu, Yu; Schoenborn, Jamie R; Morrissey, Colm et al. (2016) High-Resolution Genomic Profiling of Disseminated Tumor Cells in Prostate Cancer. J Mol Diagn 18:131-43
Morrissey, Colm; Vessella, Robert L; Lange, Paul H et al. (2016) The biology and clinical implications of prostate cancer dormancy and metastasis. J Mol Med (Berl) 94:259-65
Roudier, Martine P; Winters, Brian R; Coleman, Ilsa et al. (2016) Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer. Prostate 76:810-22
Henzler, Christine; Li, Yingming; Yang, Rendong et al. (2016) Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer. Nat Commun 7:13668
Kumar, Akash; Coleman, Ilsa; Morrissey, Colm et al. (2016) Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nat Med 22:369-78
Faltermeier, Claire M; Drake, Justin M; Clark, Peter M et al. (2016) Functional screen identifies kinases driving prostate cancer visceral and bone metastasis. Proc Natl Acad Sci U S A 113:E172-81

Showing the most recent 10 out of 157 publications